Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 27 % of short-term debt in 2024; threshold 65 %.
-
Busy address KBO
31 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
ImmunXperts from Charleroi, company number BE0552755587, closed financial year 2024 with a result of € -3 million after tax. For that financial year ImmunXperts recorded a gross margin of € 393,338 and equity of € -1.6 million. Compared with financial year 2023, the result moved from € -266,255 to € -3 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2025.
€ -1.6 million
▼ € 3 million vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3 million
▼ 1018 % more loss than in 2023
Profit after tax over the fiscal year.
€ 1.5 million
▼ 15% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.5 million.
People and assets in 2024
26.7
▲ 2.1 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 2.2 million
▼ 6% vs 2023
€ 81,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 164,086
▼ 38% vs 2023
Of which on lease € 29,548.
Debts at end 2024
€ 1.1 million
▲ € 1.1 million vs 2023
€ 30,862 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.
€ 477,953
▼ 65% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 628,084
▲ 12% vs 2023
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 2,425,427 | € 2,748,794 | € 2,563,153 | € 393,338 | ▼ 85% |
| Profit after taxes | € 238,014 | € 458,486 | € -266,255 | € -2,975,828 | ▼ € 2.7 million |
| Equity | € 1,454,403 | € 1,766,549 | € 1,403,965 | € -1,601,929 | ▼ € 3 million |
| Total debts | € 3,829,374 | € 4,893,200 | € 9,438,321 | € 11,180,449 | ▲ 18% |
| Cash | € 563,572 | € 605,203 | € 1,784,849 | € 1,511,877 | ▼ 15% |
| Retained profit | € 307,811 | € 766,297 | € 500,042 | € -2,475,785 | ▼ € 3 million |
| Bank debt | € 331,231 | € 164,924 | € 73,537 | € 1,141,541 | ▲ € 1.1 million |
| Balance sheet total | € 5,283,777 | € 6,659,749 | € 10,842,286 | € 9,578,520 | ▼ 12% |
| Employees (FTE) | 18.3 | 22 | 24.6 | 26.7 | ▲ 2.1 |
Key figures of ImmunXperts, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to ImmunXperts?
What happened at ImmunXperts in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Sofie Pattyn stepped down as director. NBB
- Clément Vanthournhout stepped down as director. NBB
- Emmanuel Vanderhaegen stepped down as director. NBB
- New annual accounts for financial year 2024: loss of € 3 million. Source: NBB ↗
- Emmanuel Vanderhaegen became a director. NBB
- Sofie Pattyn became a director. NBB
- Clément Vanthournhout became a director. NBB
- New establishment in Charleroi. KBO
In short
From € 238,014 profit in 2021 to € 3 million loss in 2024.
Paid € 5,413 in corporate taxes since 2021.
Best year ever: 2022, with € 458,486 profit.
On average € 14,700 of value added per employee in 2024.
Management
The shares are held by Nexelis Europe (100%).
Directors
According to the 2024 annual accounts
since 2022 · until 2028
since 2022 · until 2028
Emmanuel Vanderhaegen
Director
since 2023 · until 2028
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Clément Ader 10
6041 Charleroi
Rue Clément Ader 16
6041 Charleroi
Active since 16 May 2014
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.
All companies at this address →Brussels South Charleroi BioPark Dev
€ 80,186 gross margin · 2025
LYS MEDICAL
€ -309,203 gross margin · 2025
SPECTRALYS BIOTECH
€ 143,689 gross margin · 2025
ProtonW.be
€ -7,643 gross margin · 2025
QbD Wallonia
€ 1.5 million gross margin · 2025
+26 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AS-26496-GO-DADDY-COM-LLC - GoDaddy.com, LLC, US
Domain
Domain
immunxperts.com
Registered
2013-06-12
Registrar
GoDaddy.com, LLC
Expires
2026-06-12
Website info
Features
Security
Details
- Company number
- 0552.755.587
- VAT number
- BE 0552.755.587
- Registered office
- Rue Clément Ader 10, 6041 Charleroi
- Names & denominations
- ImmunXperts · IMXP
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 May 2014
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- immunxperts.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied